Asthma and COPD (chronic obstructive pulmonary disease) are a growing major health burden, which, despite improvements in disease management, still require new effective treatments. As our understanding of the cellular and molecular processes which govern respiratory diseases improves, the range of potential therapeutic targets increase. PI 3-kinases (phosphoinositide 3-kinases) are a family of closely related enzymes, which play pivotal roles in a diverse array of cellular mechanisms. In the present paper, we review the evidence for PI 3-kinase involvement in various cellular processes underlying asthma and COPD generated through inhibitor studies and gene-targeting approaches, and discuss the prospects for PI 3-kinase inhibition as a future therapeutic strategy for the treatment of respiratory disease.
Skip Nav Destination
Article navigation
April 2004
- PDF Icon PDF LinkFront Matter
Conference Article|
April 01 2004
PI 3-kinase inhibition: a therapeutic target for respiratory disease
P.M. Finan;
P.M. Finan
1
Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K.
1To whom correspondence should be addressed (e-mail peter.finan@pharma.novartis.com).
Search for other works by this author on:
M.J. Thomas
M.J. Thomas
Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K.
Search for other works by this author on:
Publisher: Portland Press Ltd
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© 2004 Biochemical Society
2004
Biochem Soc Trans (2004) 32 (2): 378–382.
Citation
P.M. Finan, M.J. Thomas; PI 3-kinase inhibition: a therapeutic target for respiratory disease. Biochem Soc Trans 1 April 2004; 32 (2): 378–382. doi: https://doi.org/10.1042/bst0320378
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.